Özlem PEKEL, Gül ERGÖR, Türkan GÜNAY, Hakan BAYDUR, BERİL CHOUSSEIN, Refik BUDAK, Sinem DOĞANAY

Smoking cessation and the effect of nicotine dependence onrelapse rate in İzmir, Turkey

Background/aim: Smoking is the leading preventable cause of death in the world. There is growing evidence of the need for community-based programs on smoking cessation. The main purpose of this study is to establish the rate of smoking cessation and restarting in 1 year at the Balçova Smoking Cessation Center. Materials and methods: This is a prospective study with a study group of 359 individuals who quit smoking at the Balçova Smoking Cessation Center for at least 4 weeks between October 2009 and April 2010. The outcomes of the study were 1-year cessation rate and relapse rate. Individuals who reported restarting and/or had CO measurements above 6 ppm were accepted as quitters who had relapsed. Results: The 1-year rate of smoking cessation was 30.1% for the study group. Of the subjects who quit smoking, 50.1% started smoking again during the 1-year follow-up. Relapse rate was also higher in nicotine addicts. Pharmacological treatment was associated with increased success rates in smoking cessation. Conclusion: Nicotine dependency was shown to be associated with lower rates of smoking cessation and higher rates of relapse. Therefore, it is important to begin smoking cessation attempts before individuals become serious addicts.

Anahtar Kelimeler:

Smoking cessation, relapse rate, pharmacological treatment

Smoking cessation and the effect of nicotine dependence onrelapse rate in İzmir, Turkey

Keywords:

Smoking cessation, relapse rate, pharmacological treatment,

PDF

___

World Health Organization. Report on the Global Tobacco Epidemic, 2008; The MPOWER Package. Geneva, Switzerland: World Health Organization; 2008.
Turkish Ministry of Health. Global Adult Tobacco Survey Report on Turkey 2010. Ankara, Turkey: Turkish Ministry of Health; 2010.
World Health Organization. Framework Convention on Tobacco Control. Geneva, Switzerland: World Health Organization; 2003.
Erguder T, Çakir B, Aslan D, Warren CW, Jones NR, Asma S. Evaluation of the use of Global Youth Tobacco Survey (GYTS) data for developing evidence-based tobacco control policies in Turkey. BMC Public Health 2008; 8: S4.
Quist-Paulsen P, Gallefoss F. Randomised controlled trial of smoking cessation intervention after admission for coronary heart disease. BMJ 2003; 327: 1254–1257.
Japuntich SJ, Leventhal AM, Piper ME, Bolt DM, Roberts LJ, Fiore MC, Baker TB. Smoker characteristics and smoking- cessation milestones. Am J Prev Med 2011; 40: 286–294.
Fagerstrom KO, Heatherton TF, Kozlowski LT. Nicotine addiction and its assessment. Ear Nose Throat J 1990; 69: 763– 765.
Dawson B, Trapp RG. Basic & Clinical Biostatistics. 4th ed. McGraw-Hill: New York, NY, USA; 2004.
Çan G, Öztuna F, Topbaş M, Özlü T. The evaluation of Karadeniz Technical University Teaching Hospital’s Smoking Cessation Clinic results for three years. Bulletin of Community Medicine 2006; 25: 22–26.
Salepçi B, Fidan A, Oruç Ö, Torun E, Çağlayan B, Kader ŞN. Success rates in our smoking cessation clinic and factors affecting it. Toraks Dergisi 2005; 2: 151–158 (in Turkish with English abstract).
Solak ZA, Gündüz Telli C, Erdinç E. Results of smoking cessation program. Toraks Dergisi 2003; 41: 73–77 (in Turkish with English abstract).
Uzaslan EK, Özyardımcı N, Karadağ M. The physician’s intervention in smoking cessation: Results of the five years of smoking cessation clinic. Ann Med Sci 2000; 9: 63–69.
Carlson LE, Goodey E, Bennett MH, Taenzer P, Koopmans J. The addition of social support to a community-based large- group behavioral smoking cessation intervention: Improved cessation rates and gender differences. Addict Behav 2002; 27: 547–559.
Herd N, Borland R, Hyland A. Predictors of smoking relapse by duration of abstinence: from the International Tobacco Control (ITC) Four Country Survey. Addiction 2009; 104: 2088–2099.
Hawkins J, Hollingworth W, Campbell R. Long-term smoking relapse: a study using the British Household Panel Survey. Nicotine Tob Res 2010; 12: 1228–1235.
Pisinger C, Aadahl M, Toft U, Jİrgensen T. Motives to quit smoking and reasons to relapse differ by socioeconomic status. Prev Med 2011; 52: 48–52.
Powell J, Dawkins L, West R, Powell J, Pickering A. Relapse to smoking during unaided cessation: clinical, cognitive and motivational predictors. Psychopharmacology (Berl) 2010; 212: 537–549.
Bolt DM, Piper ME, McCarthy DE, Japuntich SJ, Fiore MC, Smith SS, Baker TB. The Wisconsin Predicting Patients’ Relapse questionnaire. Nicotine Tob Res 2009; 11: 481–492.
Hurt RD, Wolter TD, Rigotti N, Hays JT, Niaura R, Durcan MJ, Gonzales D, Sachs DP, Johnston JA, Offord KP. Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome. Addict Behav 2002; 27: 493–507.
Tonstad S, Tİnnesen P, Hajek P, Williams KE, Billing CB, Reeves KR; Varenicline Phase 3 Study Group. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296: 64–71.
Hajek P, Stead LF, West R, Jarvis M, Hartmann-Boyce J, Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2013; 8: CD003999.
Lancaster T, Hajek P, Stead LF, West R, Jarvis MJ. Prevention of relapse after quitting smoking. Arch Intern Med 2006; 166: 828–835.